Literature DB >> 24527281

Chimeric Human Skin Substitute Tissue: A Novel Treatment Option for the Delivery of Autologous Keratinocytes.

Cathy A Rasmussen1, B Lynn Allen-Hoffmann2.   

Abstract

BACKGROUND: For patients suffering from catastrophic burns, few treatment options are available. Chimeric coculture of patient-derived autologous cells with a "carrier" cell source of allogeneic keratinocytes has been proposed as a means to address the complex clinical problem of severe skin loss. THE PROBLEM: Currently, autologous keratinocytes are harvested, cultured, and expanded to form graftable epidermal sheets. However, epidermal sheets are thin, are extremely fragile, and do not possess barrier function, which only develops as skin stratifies and matures. Grafting is typically delayed for up to 4 weeks to propagate a sufficient quantity of the patient's cells for application to wound sites. BASIC/CLINICAL SCIENCE ADVANCES: Fully stratified chimeric bioengineered skin substitutes could not only provide immediate wound coverage and restore barrier function, but would simultaneously deliver autologous keratinocytes to wounds. The ideal allogeneic cell source for this application would be an abundant supply of clinically evaluated, nontumorigenic, pathogen-free, human keratinocytes. To evaluate this potential cell-based therapy, mixed populations of a green fluorescent protein-labeled neonatal human keratinocyte cell line (NIKS) and unlabeled primary keratinocytes were used to model the allogeneic and autologous components of chimeric monolayer and organotypic cultures. CLINICAL CARE RELEVANCE: Relatively few autologous keratinocytes may be required to produce fully stratified chimeric skin substitute tissue substantially composed of autologous keratinocyte-derived regions. The need for few autologous cells interspersed within an allogeneic "carrier" cell population may decrease cell expansion time, reducing the time to patient application.
CONCLUSION: This study provides proof of concept for utilizing NIKS keratinocytes as the allogeneic carrier for the generation of bioengineered chimeric skin substitute tissues capable of providing immediate wound coverage while simultaneously supplying autologous human cells for tissue regeneration.

Entities:  

Year:  2012        PMID: 24527281      PMCID: PMC3839016          DOI: 10.1089/wound.2011.0340

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  19 in total

1.  Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS.

Authors:  B L Allen-Hoffmann; S J Schlosser; C A Ivarie; C A Sattler; L F Meisner; S L O'Connor
Journal:  J Invest Dermatol       Date:  2000-03       Impact factor: 8.551

2.  National Burn Repository 2006: a ten-year review.

Authors:  Barbara A Latenser; Sidney F Miller; Palmer Q Bessey; Susan M Browning; Daniel M Caruso; Manuel Gomez; James C Jeng; John A Krichbaum; Christopher W Lentz; Jeffrey R Saffle; Michael J Schurr; David G Greenhalgh; Richard J Kagan
Journal:  J Burn Care Res       Date:  2007 Sep-Oct       Impact factor: 1.845

Review 3.  Bioengineered skin substitutes for the management of burns: a systematic review.

Authors:  Clarabelle Pham; John Greenwood; Heather Cleland; Peter Woodruff; Guy Maddern
Journal:  Burns       Date:  2007-09-07       Impact factor: 2.744

4.  Permanent skin replacement using engineered epidermis containing fewer than 5% syngeneic keratinocytes.

Authors:  F Larochelle; G Ross; M Rouabhia
Journal:  Lab Invest       Date:  1998-09       Impact factor: 5.662

5.  Permanent skin replacement using chimeric epithelial cultured sheets comprising xenogeneic and syngeneic keratinocytes.

Authors:  M Rouabhia
Journal:  Transplantation       Date:  1996-05-15       Impact factor: 4.939

6.  Enhanced vascularization of cultured skin substitutes genetically modified to overexpress vascular endothelial growth factor.

Authors:  D M Supp; A P Supp; S M Bell; S T Boyce
Journal:  J Invest Dermatol       Date:  2000-01       Impact factor: 8.551

Review 7.  Update on tissue-engineered biological dressings.

Authors:  M Ehrenreich; Z Ruszczak
Journal:  Tissue Eng       Date:  2006-09

Review 8.  Cultured epithelial autograft (CEA) in burn treatment: three decades later.

Authors:  Bishara S Atiyeh; Michel Costagliola
Journal:  Burns       Date:  2007-04-02       Impact factor: 2.744

Review 9.  Bricks and mortar of the epidermal barrier.

Authors:  Z Nemes; P M Steinert
Journal:  Exp Mol Med       Date:  1999-03-31       Impact factor: 8.718

10.  Phase I/II clinical evaluation of StrataGraft: a consistent, pathogen-free human skin substitute.

Authors:  Michael J Schurr; Kevin N Foster; John M Centanni; Allen R Comer; April Wicks; Angela L Gibson; Christina L Thomas-Virnig; Sandy J Schlosser; Lee D Faucher; Mary A Lokuta; B Lynn Allen-Hoffmann
Journal:  J Trauma       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.